Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Filter Paper as a Blood Sample Collection Device for Newborn Screening.

Chace DH, Hannon WH.

Clin Chem. 2016 Mar;62(3):423-5. doi: 10.1373/clinchem.2015.252007. Epub 2016 Jan 21. No abstract available.

2.

Congenital adrenal hyperplasia cases identified by newborn screening in one- and two-screen states.

Held PK, Shapira SK, Hinton CF, Jones E, Hannon WH, Ojodu J.

Mol Genet Metab. 2015 Nov;116(3):133-8. doi: 10.1016/j.ymgme.2015.08.004. Epub 2015 Aug 12.

3.

Newborn blood spot screening test using multiplexed real-time PCR to simultaneously screen for spinal muscular atrophy and severe combined immunodeficiency.

Taylor JL, Lee FK, Yazdanpanah GK, Staropoli JF, Liu M, Carulli JP, Sun C, Dobrowolski SF, Hannon WH, Vogt RF.

Clin Chem. 2015 Feb;61(2):412-9. doi: 10.1373/clinchem.2014.231019. Epub 2014 Dec 11.

4.

Performance of succinylacetone assays and their associated proficiency testing outcomes.

Adam BW, Hall EM, Meredith NK, Lim TH, Haynes CA, De Jesus VR, Hannon WH.

Clin Biochem. 2012 Dec;45(18):1658-63. doi: 10.1016/j.clinbiochem.2012.08.007. Epub 2012 Aug 11.

5.

Immunoreactive Trypsinogen (IRT) as a Biomarker for Cystic Fibrosis: challenges in newborn dried blood spot screening.

Therrell BL Jr, Hannon WH, Hoffman G, Ojodu J, Farrell PM.

Mol Genet Metab. 2012 May;106(1):1-6. doi: 10.1016/j.ymgme.2012.02.013. Epub 2012 Feb 28.

PMID:
22425451
6.

Newborn dried blood spot screening: residual specimen storage issues.

Therrell BL Jr, Hannon WH.

Pediatrics. 2012 Feb;129(2):365-6. doi: 10.1542/peds.2011-3416. Epub 2012 Jan 16. No abstract available.

PMID:
22250020
7.

CFTR mutation analysis and haplotype associations in CF patients.

Cordovado SK, Hendrix M, Greene CN, Mochal S, Earley MC, Farrell PM, Kharrazi M, Hannon WH, Mueller PW.

Mol Genet Metab. 2012 Feb;105(2):249-54. doi: 10.1016/j.ymgme.2011.10.013. Epub 2011 Oct 26.

8.

The stability of markers in dried-blood spots for recommended newborn screening disorders in the United States.

Adam BW, Hall EM, Sternberg M, Lim TH, Flores SR, O'Brien S, Simms D, Li LX, De Jesus VR, Hannon WH.

Clin Biochem. 2011 Dec;44(17-18):1445-50. doi: 10.1016/j.clinbiochem.2011.09.010. Epub 2011 Sep 21.

9.

Committee report: Considerations and recommendations for national guidance regarding the retention and use of residual dried blood spot specimens after newborn screening.

Therrell BL Jr, Hannon WH, Bailey DB Jr, Goldman EB, Monaco J, Norgaard-Pedersen B, Terry SF, Johnson A, Howell RR.

Genet Med. 2011 Jul;13(7):621-4. doi: 10.1097/GIM.0b013e3182147639.

PMID:
21602691
10.

Detection of TPN contamination of dried blood spots used in newborn and metabolic screening and its impact on quantitative measurement of amino acids.

Chace DH, De Jesús VR, Lim TH, Hannon WH, Clark RH, Spitzer AR.

Clin Chim Acta. 2011 Jul 15;412(15-16):1385-90. doi: 10.1016/j.cca.2011.04.009. Epub 2011 Apr 14.

PMID:
21514290
11.

Implementation of the first worldwide quality assurance program for cystic fibrosis multiple mutation detection in population-based screening.

Earley MC, Laxova A, Farrell PM, Driscoll-Dunn R, Cordovado S, Mogayzel PJ Jr, Konstan MW, Hannon WH.

Clin Chim Acta. 2011 Jul 15;412(15-16):1376-81. doi: 10.1016/j.cca.2011.04.011. Epub 2011 Apr 14.

12.

The preparation and storage of dried-blood spot quality control materials for lysosomal storage disease screening tests.

Adam BW, Orsini JJ Jr, Martin M, Hall EM, Zobel SD, Caggana M, Hannon WH.

Clin Biochem. 2011 Jun;44(8-9):704-10. doi: 10.1016/j.clinbiochem.2011.02.014. Epub 2011 Mar 4.

PMID:
21382365
13.

Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project.

McHugh D, Cameron CA, Abdenur JE, Abdulrahman M, Adair O, Al Nuaimi SA, Åhlman H, Allen JJ, Antonozzi I, Archer S, Au S, Auray-Blais C, Baker M, Bamforth F, Beckmann K, Pino GB, Berberich SL, Binard R, Boemer F, Bonham J, Breen NN, Bryant SC, Caggana M, Caldwell SG, Camilot M, Campbell C, Carducci C, Bryant SC, Caggana M, Caldwell SG, Camilot M, Campbell C, Carducci C, Cariappa R, Carlisle C, Caruso U, Cassanello M, Castilla AM, Ramos DE, Chakraborty P, Chandrasekar R, Ramos AC, Cheillan D, Chien YH, Childs TA, Chrastina P, Sica YC, de Juan JA, Colandre ME, Espinoza VC, Corso G, Currier R, Cyr D, Czuczy N, D'Apolito O, Davis T, de Sain-Van der Velden MG, Delgado Pecellin C, Di Gangi IM, Di Stefano CM, Dotsikas Y, Downing M, Downs SM, Dy B, Dymerski M, Rueda I, Elvers B, Eaton R, Eckerd BM, El Mougy F, Eroh S, Espada M, Evans C, Fawbush S, Fijolek KF, Fisher L, Franzson L, Frazier DM, Garcia LR, Bermejo MS, Gavrilov D, Gerace R, Giordano G, Irazabal YG, Greed LC, Grier R, Grycki E, Gu X, Gulamali-Majid F, Hagar AF, Han L, Hannon WH, Haslip C, Hassan FA, He M, Hietala A, Himstedt L, Hoffman GL, Hoffman W, Hoggatt P, Hopkins PV, Hougaard DM, Hughes K, Hunt PR, Hwu WL, Hynes J, Ibarra-González I, Ingham CA, Ivanova M, Jacox WB, John C, Johnson JP, Jónsson JJ, Karg E, Kasper D, Klopper B, Katakouzinos D, Khneisser I, Knoll D, Kobayashi H, Koneski R, Kozich V, Kouapei R, Kohlmueller D, Kremensky I, la Marca G, Lavochkin M, Lee SY, Lehotay DC, Lemes A, Lepage J, Lesko B, Lewis B, Lim C, Linard S, Lindner M, Lloyd-Puryear MA, Lorey F, Loukas YL, Luedtke J, Maffitt N, Magee JF, Manning A, Manos S, Marie S, Hadachi SM, Marquardt G, Martin SJ, Matern D, Mayfield Gibson SK, Mayne P, McCallister TD, McCann M, McClure J, McGill JJ, McKeever CD, McNeilly B, Morrissey MA, Moutsatsou P, Mulcahy EA, Nikoloudis D, Norgaard-Pedersen B, Oglesbee D, Oltarzewski M, Ombrone D, Ojodu J, Papakonstantinou V, Reoyo SP, Park HD, Pasquali M, Pasquini E, Patel P, Pass KA, Peterson C, Pettersen RD, Pitt JJ, Poh S, Pollak A, Porter C, Poston PA, Price RW, Queijo C, Quesada J, Randell E, Ranieri E, Raymond K, Reddic JE, Reuben A, Ricciardi C, Rinaldo P, Rivera JD, Roberts A, Rocha H, Roche G, Greenberg CR, Mellado JM, Juan-Fita MJ, Ruiz C, Ruoppolo M, Rutledge SL, Ryu E, Saban C, Sahai I, García-Blanco MI, Santiago-Borrero P, Schenone A, Schoos R, Schweitzer B, Scott P, Seashore MR, Seeterlin MA, Sesser DE, Sevier DW, Shone SM, Sinclair G, Skrinska VA, Stanley EL, Strovel ET, Jones AL, Sunny S, Takats Z, Tanyalcin T, Teofoli F, Thompson JR, Tomashitis K, Domingos MT, Torres J, Torres R, Tortorelli S, Turi S, Turner K, Tzanakos N, Valiente AG, Vallance H, Vela-Amieva M, Vilarinho L, von Döbeln U, Vincent MF, Vorster BC, Watson MS, Webster D, Weiss S, Wilcken B, Wiley V, Williams SK, Willis SA, Woontner M, Wright K, Yahyaoui R, Yamaguchi S, Yssel M, Zakowicz WM.

Genet Med. 2011 Mar;13(3):230-54. doi: 10.1097/GIM.0b013e31820d5e67.

PMID:
21325949
14.

Proficiency testing outcomes of 3-hydroxyisovalerylcarnitine measurements by tandem mass spectrometry in newborn screening.

Lim TH, De Jesús VR, Meredith NK, Sternberg MR, Chace DH, Mei JV, Hannon WH.

Clin Chim Acta. 2011 Mar 18;412(7-8):631-5. doi: 10.1016/j.cca.2010.12.021. Epub 2010 Dec 23.

PMID:
21185274
15.

Effect of specimen storage conditions on newborn dried blood spots used to assess Toxoplasma gondii immunoglobulin M (IgM).

Mei JV, Li L, Rasmussen SA, Collier S, Frias JL, Honein MA, Shaw GM, Lorey F, Meyer R, Chaing S, Canfield MA, Jones J, Hannon WH.

Clin Chim Acta. 2011 Feb 20;412(5-6):455-9. doi: 10.1016/j.cca.2010.11.028. Epub 2010 Nov 27.

PMID:
21114968
16.

Performance properties of filter paper devices for whole blood collection.

Mei JV, Zobel SD, Hall EM, De Jesús VR, Adam BW, Hannon WH.

Bioanalysis. 2010 Aug;2(8):1397-403. doi: 10.4155/bio.10.73.

PMID:
21083340
17.

Impact of second-tier testing on the effectiveness of newborn screening.

Chace DH, Hannon WH.

Clin Chem. 2010 Nov;56(11):1653-5. doi: 10.1373/clinchem.2010.153494. Epub 2010 Sep 13. No abstract available.

18.

Tandem mass spectrometric identification of dextrose markers in dried-blood spots from infants receiving total parenteral nutrition.

Chace DH, De Jesús VR, Lim TH, Hannon WH, Spitzer AR.

Clin Chim Acta. 2010 Nov 11;411(21-22):1806-16. doi: 10.1016/j.cca.2010.08.007. Epub 2010 Aug 11.

PMID:
20707991
19.

Proficiency testing of human leukocyte antigen-DR and human leukocyte antigen-DQ genetic risk assessment for type 1 diabetes using dried blood spots.

Dantonio P, Meredith-Molloy N, Hagopian WA, She JX, Akolkar B, Cordovado SK, Hendrix M, Henderson LO, Hannon WH, Vogt RF.

J Diabetes Sci Technol. 2010 Jul 1;4(4):929-41.

20.

Pilot proficiency testing study for second tier congenital adrenal hyperplasia newborn screening.

De Jesús VR, Simms DA, Schiffer J, Kennedy M, Mei JV, Hannon WH.

Clin Chim Acta. 2010 Nov 11;411(21-22):1684-7. doi: 10.1016/j.cca.2010.06.029. Epub 2010 Jul 6.

PMID:
20619255
21.

Potential loss of methionine following extended storage of newborn screening samples prepared for tandem mass spectrometry analysis.

Chace DH, Luo Z, De Jesús VR, Haynes CA, Hannon WH.

Clin Chim Acta. 2010 Sep 6;411(17-18):1284-6. doi: 10.1016/j.cca.2010.05.011. Epub 2010 May 15.

PMID:
20478282
22.

Maternal and neonatal vitamin B12 deficiency detected through expanded newborn screening--United States, 2003-2007.

Hinton CF, Ojodu JA, Fernhoff PM, Rasmussen SA, Scanlon KS, Hannon WH.

J Pediatr. 2010 Jul;157(1):162-3. doi: 10.1016/j.jpeds.2010.03.006. Epub 2010 Apr 18.

PMID:
20400092
23.

Improving and assuring newborn screening laboratory quality worldwide: 30-year experience at the Centers for Disease Control and Prevention.

De Jesús VR, Mei JV, Bell CJ, Hannon WH.

Semin Perinatol. 2010 Apr;34(2):125-33. doi: 10.1053/j.semperi.2009.12.003.

PMID:
20207262
24.

Newborn Screening System Performance Evaluation Assessment Scheme (PEAS).

Therrell BL Jr, Schwartz M, Southard C, Williams D, Hannon WH, Mann MY; PEAS Organizing and Working Groups.

Semin Perinatol. 2010 Apr;34(2):105-20. doi: 10.1053/j.semperi.2009.12.002.

PMID:
20207260
25.

Comparison of amino acids and acylcarnitines assay methods used in newborn screening assays by tandem mass spectrometry.

De Jesús VR, Chace DH, Lim TH, Mei JV, Hannon WH.

Clin Chim Acta. 2010 May 2;411(9-10):684-9. doi: 10.1016/j.cca.2010.01.034. Epub 2010 Feb 1.

PMID:
20122909
26.

Preliminary proficiency testing results for succinylacetone in dried blood spots for newborn screening for tyrosinemia type I.

Adam BW, Lim TH, Hall EM, Hannon WH.

Clin Chem. 2009 Dec;55(12):2207-13. doi: 10.1373/clinchem.2009.133819. Epub 2009 Oct 22.

27.

National academy of clinical biochemistry laboratory medicine practice guidelines: follow-up testing for metabolic disease identified by expanded newborn screening using tandem mass spectrometry; executive summary.

Dietzen DJ, Rinaldo P, Whitley RJ, Rhead WJ, Hannon WH, Garg UC, Lo SF, Bennett MJ.

Clin Chem. 2009 Sep;55(9):1615-26. doi: 10.1373/clinchem.2009.131300. Epub 2009 Jul 2.

28.

Improved MS/MS analysis of succinylacetone extracted from dried blood spots when combined with amino acids and acylcarnitine butyl esters.

Chace DH, Lim T, Hansen CR, De Jesus VR, Hannon WH.

Clin Chim Acta. 2009 Sep;407(1-2):6-9. doi: 10.1016/j.cca.2009.06.017. Epub 2009 Jun 21.

PMID:
19545553
29.

Changes in solvent composition in tandem mass spectrometry multiplex assay for lysosomal storage disorders do not affect assay results.

De Jesus VR, Zhou H, Vogt RF, Hannon WH.

Clin Chem. 2009 Mar;55(3):596-8. doi: 10.1373/clinchem.2008.122176. No abstract available.

30.

Assessment of DNA contamination from dried blood spots and determination of DNA yield and function using archival newborn dried blood spots.

Cordovado SK, Earley MC, Hendrix M, Driscoll-Dunn R, Glass M, Mueller PW, Hannon WH.

Clin Chim Acta. 2009 Apr;402(1-2):107-13. doi: 10.1016/j.cca.2008.12.028. Epub 2008 Dec 31.

PMID:
19161996
31.

Quantification of malonylcarnitine in dried blood spots by use of MS/MS varies by stable isotope internal standard composition.

Chace DH, Lim T, Hansen CR, Adam BW, Hannon WH.

Clin Chim Acta. 2009 Apr;402(1-2):14-8. doi: 10.1016/j.cca.2008.10.035. Epub 2008 Nov 13.

PMID:
19041298
32.

Development and evaluation of quality control dried blood spot materials in newborn screening for lysosomal storage disorders.

De Jesus VR, Zhang XK, Keutzer J, Bodamer OA, Mühl A, Orsini JJ, Caggana M, Vogt RF, Hannon WH.

Clin Chem. 2009 Jan;55(1):158-64. doi: 10.1373/clinchem.2008.111864. Epub 2008 Nov 6.

33.

First ISNS Reference Preparation for Neonatal Screening for thyrotropin, phenylalanine and 17alpha-hydroxyprogesterone in blood spots.

Elvers LH, Loeber JG, Dhondt JL, Fukushi M, Hannon WH, Torresani T, Webster D.

J Inherit Metab Dis. 2007 Aug;30(4):609. Epub 2007 Jun 14.

PMID:
17574536
34.

National evaluation of US newborn screening system components.

Therrell BL, Hannon WH.

Ment Retard Dev Disabil Res Rev. 2006;12(4):236-45.

PMID:
17183567
35.

A screening system for detecting genetic risk markers of type 1 diabetes in dried blood spots.

Dantonio P, Meredith N, Earley M, Cordovado S, Callan WJ, Rollin D, Morris D, Vogt RF, Hannon WH.

Diabetes Technol Ther. 2006 Aug;8(4):433-43.

PMID:
16939368
36.

Development and characterization of dried blood spot materials for the measurement of immunoreactive trypsinogen.

Li L, Zhou Y, Bell CJ, Earley MC, Hannon WH, Mei JV.

J Med Screen. 2006;13(2):79-84.

PMID:
16792830
37.

Storage and use of residual dried blood spots from state newborn screening programs.

Olney RS, Moore CA, Ojodu JA, Lindegren ML, Hannon WH.

J Pediatr. 2006 May;148(5):618-22.

PMID:
16737872
38.

Naming and counting disorders (conditions) included in newborn screening panels.

Sweetman L, Millington DS, Therrell BL, Hannon WH, Popovich B, Watson MS, Mann MY, Lloyd-Puryear MA, van Dyck PC.

Pediatrics. 2006 May;117(5 Pt 2):S308-14.

PMID:
16735257
39.

Metabolic disorders detectable by tandem mass spectrometry and unexpected early childhood mortality: a population-based study.

Dott M, Chace D, Fierro M, Kalas TA, Hannon WH, Williams J, Rasmussen SA.

Am J Med Genet A. 2006 Apr 15;140(8):837-42.

PMID:
16528746
40.

Performance evaluation for screening laboratories of the Asia-Pacific region.

Hannon WH.

Southeast Asian J Trop Med Public Health. 2003;34 Suppl 3:39-42.

PMID:
15906691
41.

Applying public health strategies to primary immunodeficiency diseases: a potential approach to genetic disorders.

Lindegren ML, Kobrynski L, Rasmussen SA, Moore CA, Grosse SD, Vanderford ML, Spira TJ, McDougal JS, Vogt RF Jr, Hannon WH, Kalman LV, Chen B, Mattson M, Baker TG, Khoury M.

MMWR Recomm Rep. 2004 Jan 16;53(RR-1):1-29. Review.

42.

Newborn screening and type 1 diabetes: historical perspective and current activities at the CDC Division of Laboratory Sciences.

Vogt RF Jr, Meredith N, Henderson LO, Hannon WH.

Diabetes Technol Ther. 2003;5(6):1017-21. No abstract available.

PMID:
14709205
43.

Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence.

Kothe D, Byers RH, Caudill SP, Satten GA, Janssen RS, Hannon WH, Mei JV.

J Acquir Immune Defic Syndr. 2003 Aug 15;33(5):625-34.

PMID:
12902808
44.

Report from a workshop on multianalyte microsphere assays.

Earley MC, Vogt RF Jr, Shapiro HM, Mandy FF, Kellar KL, Bellisario R, Pass KA, Marti GE, Stewart CC, Hannon WH.

Cytometry. 2002 Oct 15;50(5):239-42.

45.

Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).

Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE.

J Clin Endocrinol Metab. 2002 Feb;87(2):489-99.

PMID:
11836274
46.

Current activities at the Centers for Disease Control and Prevention's National Diabetes Laboratory.

Sampson EJ, Barr JR, Cordovado SK, Hannon WH, Henderson LO, Johnson AB, Miller D, Mueller PW, Myers GL, Pirkle JL, Schleicher RL, Steinberg K, Sussman D, Vogt RF.

Diabetes Technol Ther. 1999 Winter;1(4):403-9.

PMID:
11474824
47.

Early diagnosis of cystic fibrosis.

Grosse SD, Khoury MJ, Hannon WH, Boyle CA, Farrell PM.

Pediatrics. 2001 Jun;107(6):1492. No abstract available.

PMID:
11400707
48.

Measures of maternal tobacco exposure and infant birth weight at term.

England LJ, Kendrick JS, Gargiullo PM, Zahniser SC, Hannon WH.

Am J Epidemiol. 2001 May 15;153(10):954-60.

PMID:
11384951
49.

Use of filter paper for the collection and analysis of human whole blood specimens.

Mei JV, Alexander JR, Adam BW, Hannon WH.

J Nutr. 2001 May;131(5):1631S-6S. Review.

PMID:
11340130
50.

Errors caused by the use of D,L-octanoylcarnitine for blood-spot calibrators.

Chace DH, DiPerna JC, Adam BW, Hannon WH.

Clin Chem. 2001 Apr;47(4):758-60. No abstract available.

Supplemental Content

Loading ...
Support Center